Trial Profile

The Effect of Multiple Doses of Cenobamate (YKP3089) on the Single Dose Pharmacokinetics of Cytochrome P450 Substrates (Midazolam, Warfarin, Omeprazole and Bupropion) Administered Orally in an Open-label, One-sequence Study in Healthy Subjects

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 25 Sep 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cenobamate (Primary) ; Bupropion; Midazolam; Omeprazole; Warfarin
Indications Anxiety disorders; Bipolar disorders; Neuropathic pain; Partial epilepsies
Focus Pharmacokinetics
Sponsors SK Life Science

16 Mar 2019 Results assessing the effect of Cenobamate on the single dose pharmacokinetics of multiple CYP450 probes using cocktail approach in healthy subjects, were presented at the 120th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.
07 Aug 2017 Status changed from active, no longer recruiting to completed.
02 Aug 2017 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com